This inventor holds 2 USPTO granted patents. Top assignee: Yale University. Active years: 2004-2009.
Location History:
- La Mesa, CA (US) (2004)
- Le Mesa, CA (US) (2009)
Company Filing History:
Years Active: 2004-2009
Title: Ute Splittgerber: Innovator in Enzyme Inhibition
Introduction
Ute Splittgerber is a prominent inventor based in La Mesa, California. She has made significant contributions to the field of enzyme inhibition, particularly through her innovative peptide-based compounds. With a total of 2 patents, her work has implications for therapeutic applications.
Latest Patents
Ute's latest patents focus on enzyme inhibition using peptide-based compounds that include heteroatom-containing, three-membered rings. These compounds efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of Ntn hydrolases, which can have multiple functions, can be differentially inhibited by the compounds she has developed. For instance, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited using her inventive compounds. The peptide-based compounds are designed to include an electron-withdrawing group adjacent to the ring functionality, and they consist of at least three peptide units. Among their various therapeutic utilities, these compounds exhibit anti-inflammatory properties and inhibit cell proliferation, showcasing their potential for therapeutic applications.
Career Highlights
Ute Splittgerber is affiliated with Yale University, where she continues her research and development in the field of enzyme inhibition. Her work has garnered attention for its innovative approach and potential impact on therapeutic strategies.
Collaborations
Ute collaborates with Craig M. Crews, further enhancing her research endeavors and contributing to advancements in the field.
Conclusion
Ute Splittgerber's contributions to enzyme inhibition through her innovative peptide-based compounds highlight her role as a significant inventor in the scientific community. Her work not only advances our understanding of enzyme activity but also opens new avenues for therapeutic applications.